Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Ema LupšićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0001-7824-1689
Pavle StojkovićUniversity of Belgrade-Faculty of Chemistry, P.O. Box 51, Studentski Trg 16, 11158 Belgrade, Serbia.ORCID 0000-0002-4660-5537
Marija GrozdanićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0009-0007-7425-685X
Nataša Terzić-JovanovićUniversity of Belgrade-Institute of Chemistry, Technology, and Metallurgy, National Institute of the Republic of Serbia, Njegoševa 12, 11000 Belgrade, Serbia.ORCID 0000-0002-4127-525X
Milica PajovićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0001-7312-0861
Fani KoutsougianniDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Panepistimiou 3 (Biopolis), 41500 Larissa, Greece.
Dimitra AlexopoulouDepartment of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Panepistimiou 3 (Biopolis), 41500 Larissa, Greece.
Igor M OpsenicaUniversity of Belgrade-Faculty of Chemistry, P.O. Box 51, Studentski Trg 16, 11158 Belgrade, Serbia.
Milica PešićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0002-9045-8239
Ana Podolski-RenićInstitute for Biological Research "Siniša Stanković"-National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0001-7412-3685
Funding
Science Fund of the Republic of Serbia 7005
6 · The paper itself
Abstract
Multidrug resistance (MDR) presents a significant challenge in the treatment of glioblastoma. We evaluated six novel adamantane-sclareol hybrids that integrate a natural labdane diterpene scaffold with an adamantane moiety to address this issue. Compounds
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel Adamantane-Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells. · full record | OpenQuestion